Last reviewed · How we verify
tripotassium dicitrate bismuthate
Tripotassium dicitrate bismuthate, marketed by Seoul National University Bundang Hospital, holds a unique position in the therapeutic landscape with its key composition patent expiring in 2028. The drug's primary strength lies in its distinct mechanism of action, which differentiates it from existing treatments. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | tripotassium dicitrate bismuthate |
|---|---|
| Sponsor | Seoul National University Bundang Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection (NA)
- Tegoprazan- Versus PPI-based H. Pylori Eradication
- Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication (PHASE4)
- Bismuth for PCAB-based H. Pylori Eradication
- Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: